ADVFN Logo ADVFN
市場データ
ニュース
投資ツール
市場
発見

Hot Features

Follow Feed

フォローフィードコミュニティでトレーダーや投資家とつながりましょう.

ライブオプションフロー

包括的なオプション データを調査し、オプション フローで高度なフィルターを使用します.

モニター

ターミナル モニターで株式と資産のウォッチリストを整理および監視します
サインイン Premium Iconプレミアム Help Menu
Bitcoin
97,612.70
-0.25%
S&P 500
6,029.25
-0.14%
Dow Jones
44,594.88
0.09%
US Dollar vs Yen
152.3185
-1.18%
Brent Oil
74.555
-1.82%
Registration Strip Icon for charts 登録してリアルタイムのチャート、分析ツール、価格を入手してください。
登録
  1. ホーム
  2. 投資
  3. 株式
  4. アメリカ
  5. NASDAQ

  6. Immunocore Holdings PLC (IMCR) 銘柄情報

Immunocore Holdings PLC

Immunocore Holdings PLC (IMCR)

NASDAQ
30.91
0.15
( 0.49% )
更新日時： 01:11:34
15分遅延

個人投資家向けのプロ仕様のツール。

プレミアム

主要統計と詳細

通貨
30.91
買値
30.78
売値
31.05
出来高
99,664
30.51 日の範囲 31.38
0.00 52 週間の範囲 0.00
時価総額
1.486B
前日終値
30.76
始値
30.65
時刻
7
@
30.79
最終取引時間
01:12:52
財務取引量
US$ 3,122,035
VWAP
31.3256
平均取引量 (3 か月)
-
発行済株式数
48,088,346
配当利回り
-
PER
-26.96
1 株当たり利益 (EPS)
-1.15
歳入
249.43M
純利益
-55.29M

Immunocore Holdings PLC について

Immunocore Holdings PLC is a late-stage biotechnology company engaged in the development of a novel class of TCR bispecific immunotherapies for the treatment of cancer, infectious and autoimmune diseases. Its geographical segments are the United Kingdom and the United States, of which the majority o... Immunocore Holdings PLC is a late-stage biotechnology company engaged in the development of a novel class of TCR bispecific immunotherapies for the treatment of cancer, infectious and autoimmune diseases. Its geographical segments are the United Kingdom and the United States, of which the majority of its revenue comes from the United States. 詳細を表示

セクター
Noncomml Resh Organizations
業界
Noncomml Resh Organizations
ウェブサイト
www.immunocore.com
本社
Oxfordshire, Gbr
設立
-
Immunocore Holdings PLC is listed in the Noncomml Resh Organizations sector of the ナスダック市場 with ticker IMCR. The last closing price for Immunocore was US$30.76. Over the last year, Immunocore shares have traded in a share price range of US$ 0.00 to US$ 0.00.

Immunocore currently has 48,088,346 shares in issue. The market capitalisation of Immunocore is US$1.48 billion. Immunocore has a price to earnings ratio (PE ratio) of -26.96.

IMCR 最新ニュース

その他のニュース

Form 8-K - Current report

2025年1月11日
Edgar (US Regulatory)

Immunocore announces strategic priorities at 43rd Annual J.P. Morgan Healthcare Conference

 Reaching more mUM patients globally with KIMMTRAK (tebentafusp) in 2025 through additional launches and increased community penetration Enrolling three Phase 3 trials across multiple melanoma...

2025年1月10日
GlobeNewswire Inc.

Immunocore to present at the 43rd Annual J.P. Morgan Healthcare Conference

Immunocore to present at the 43rd Annual J.P. Morgan Healthcare Conference (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & GAITHERSBURG, Md., US, 6 January 2025) Immunocore Holdings plc...

2025年1月6日
GlobeNewswire Inc.

Form 8-K - Current report

2025年1月2日
Edgar (US Regulatory)

Immunocore appoints Travis Coy, previously a Non-Executive Director, as its EVP, Chief Financial Officer and Head of Corporate Development

Immunocore appoints Travis Coy, previously a Non-Executive Director, as its EVP, Chief Financial Officer and Head of Corporate Development (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. &...

2025年1月2日
GlobeNewswire Inc.

Immunocore announces first patient dosed in the Phase 1 trial of IMC-P115C, a half-life extended (HLE) ImmTAC candidate in patients with tumors that express PRAME

Immunocore announces first patient dosed in the Phase 1 trial of IMC-P115C, a half-life extended (HLE) ImmTAC candidate in patients with tumors that express PRAME IMC-P115C (PRAME-HLE-A02...

2024年12月23日
GlobeNewswire Inc.

Immunocore announces treatment of first patient in the Phase 1/2 trial of IMC-R117C targeting PIWIL1 in advanced gastrointestinal cancers

The Phase 1/2 trial will assess the safety and clinical activity of IMC-R117C, as a monotherapy and in combination with standards of care, in patients with advanced cancers expressing PIWIL1...

2024年12月17日
GlobeNewswire Inc.

EORTC and Immunocore announce enrolment of first patient onto the only active Phase 3 adjuvant trial in uveal melanoma

ATOM is the only active Phase 3 trial for adjuvant treatment of uveal melanoma The trial will assess whether adjuvant treatment with tebentafusp can decrease the risk of relapse, compared to...

2024年12月11日
GlobeNewswire Inc.

Immunocore announces reimbursement agreement in England for KIMMTRAK▼ for the treatment of HLA-A*02:01-positive adults with unresectable or metastatic uveal melanoma

Immunocore announces reimbursement agreement in England for KIMMTRAK▼ for the treatment of HLA-A*02:01-positive adults with unresectable or metastatic uveal melanoma (OXFORDSHIRE, England &...

2024年12月3日
GlobeNewswire Inc.

Form 8-K - Current report

2024年11月9日
Edgar (US Regulatory)
期間 †前日比前日比 %始値高値安値平均出来高VWAP
10000000DR
40000000DR
120000000DR
260000000DR
520000000DR
1560000000DR
2600000000DR

IMCR - Frequently Asked Questions (FAQ)

What is the current Immunocore share price?
The current share price of Immunocore is US$ 30.91
How many Immunocore shares are in issue?
Immunocore has 48,088,346 shares in issue
What is the market cap of Immunocore?
The market capitalisation of Immunocore is USD 1.48B
What is the 1 year trading range for Immunocore share price?
Immunocore has traded in the range of US$ 0.00 to US$ 0.00 during the past year
What is the PE ratio of Immunocore?
The price to earnings ratio of Immunocore is -26.96
What is the cash to sales ratio of Immunocore?
The cash to sales ratio of Immunocore is 5.98
What is the reporting currency for Immunocore?
Immunocore reports financial results in USD
What is the latest annual turnover for Immunocore?
The latest annual turnover of Immunocore is USD 249.43M
What is the latest annual profit for Immunocore?
The latest annual profit of Immunocore is USD -55.29M
What is the registered address of Immunocore?
The registered address for Immunocore is 92 PARK DRIVE, MILTON PARK, ABINGDON, OXFORDSHIRE, OX14 4RY
What is the Immunocore website address?
The website address for Immunocore is www.immunocore.com
Which industry sector does Immunocore operate in?
Immunocore operates in the NONCOMML RESH ORGANIZATIONS sector

ムーバー

すべて表示
  • 出来高
  • 値上がり率
  • 値下がり率
銘柄コード株価出来高
RNAZTransCode Therapeutics Inc
US$ 11.68
(89.61%)
11.23M
ASSTAsset Entities Inc
US$ 0.8367
(52.32%)
122.62M
ACBAurora Cannabis Inc
US$ 5.4499
(48.10%)
52.51M
KTTAPasithea Therapeutics Corporation
US$ 3.058
(47.02%)
53.39M
BSLKBolt Projects Holdings Inc
US$ 0.433237
(30.49%)
2.58M
VLCNVolcon Inc
US$ 1.90
(-40.63%)
2.65M
CSAICloudastructure Inc
US$ 8.89
(-31.51%)
95.18k
LYTLytus Technologies Holdings PTV Ltd
US$ 0.417
(-30.91%)
770.62k
SDASunCar Technology Group Inc
US$ 7.68
(-25.44%)
408.73k
LTRYLottery com Inc
US$ 0.4581
(-22.04%)
3.86M
CYNCYNGN Inc
US$ 0.0901
(26.90%)
349.64M
RIMEAlgorhythm Holdings Inc
US$ 0.0197
(-19.26%)
146M
ASSTAsset Entities Inc
US$ 0.8367
(52.32%)
122.62M
NVDANVIDIA Corporation
US$ 123.17
(3.81%)
108.68M
EDBLEdible Garden AG Inc
US$ 0.1939
(-7.62%)
59.41M

IMCR Discussion

投稿を表示

最近閲覧した銘柄

NASDAQ
IMCR
Immunocore
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

日本
会社情報
ビジネス
人気
アプリを入手
App Store
Google Play

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約

© 2025 ADVFN PLC - 全著作権所有

広告を削除する

サインアップして広告なしのエクスペリエンスを体験してください

広告なし

今すぐ試してください

広告を残す